StockData

Cardio Diagnostics vs PRF Technologies

CDIO and PRFX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CDIO and PRFX compare

PRF Technologies keeps more of each dollar of sales as profit, with a net margin of −29541% compared with −42722% at Cardio Diagnostics.

PRF Technologies scores higher on the StockData Score (6 against 4 for Cardio Diagnostics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCDIOPRFX
Size and price
Market cap$5.7M–
Share price$1.92$0.744
Change, 1 year−50.3%−84.1%
Change, 5 years–−99.9%
Beta (5Y)2.651.61
Employees76
StockData Score
Total score46 (better)
Valuation score1 (better)0
Growth score1 (better)0
Performance score11
Health score15 (better)
Dividend score00
Valuation
P/S374×–
P/B1.0×–
FCF yield−102%–
Profitability
Gross margin–−312%
Operating margin−42650%−30129% (better)
Net margin−42722%−29541% (better)
FCF margin−38091%−23277% (better)
Return on equity−93.5%−41.3% (better)
Return on invested capital−136%−87.0% (better)
Financial health
Debt / equity–0.00
Interest coverage−564.9×–
Current ratio17.44 (better)5.07
Altman Z-score−1.27–
Piotroski F-score24 (better)
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions24.3%24.5%
Held by insiders2.7%24.1%
Short interest, % of float–2.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.